

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** Unknown  
**Gender:** Unknown  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Dermatomyositis and Polymyositis Panel**

ARUP test code 3018866

Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG	<b>55 AU/mL</b>	<b>H</b>	<b>(Ref Interval: 0-40)</b>
INTERPRETIVE INFORMATION: Jo-1 Antibody, IgG  29 AU/mL or less.....Negative 30-40 AU/mL.....Equivocal 41 AU/mL or greater.....Positive  Presence of Jo-1 (antihistidyl transfer RNA [t-RNA] synthetase) antibody is associated with polymyositis and may also be seen in patients with dermatomyositis. Jo-1 antibody is associated with pulmonary involvement (interstitial lung disease), Raynaud phenomenon, arthritis, and mechanic's hands (implicated in antisynthetase syndrome).			
PL-12 (alanyl-tRNA synthetase) Antibody	<b>Positive</b>	<b>*</b>	<b>(Ref Interval: Negative)</b>
PL-7 (threonyl-tRNA synthetase) Antibody	<b>Positive</b>	<b>*</b>	<b>(Ref Interval: Negative)</b>
EJ (glycyl-tRNA synthetase) Antibody	<b>Positive</b>	<b>*</b>	<b>(Ref Interval: Negative)</b>
OJ (isoleucyl-tRNA synthetase) Antibody	<b>Positive</b>	<b>*</b>	<b>(Ref Interval: Negative)</b>
SRP (Signal Recognition Particle) Ab	<b>Positive</b>	<b>*</b>	<b>(Ref Interval: Negative)</b>
Mi-2 (nuclear helicase protein) Antibody	<b>Positive</b>	<b>*</b>	<b>(Ref Interval: Negative)</b>
P155/140 Antibody	<b>Positive</b>	<b>*</b>	<b>(Ref Interval: Negative)</b>
TIF-1 gamma (155 kDa) Ab	<b>Low Positive</b>	<b>*</b>	<b>(Ref Interval: Negative)</b>

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

Low positive reactivity to transcriptional intermediary factor (TIFly) detected. Strong clinical correlation is recommended.

SAE1 (SUMO activating enzyme) Ab **Positive** \* (Ref Interval: Negative)

MDA5 (CADM-140) Ab **High Positive** \* (Ref Interval: Negative)

NXP2 (Nuclear matrix protein-2) Ab **Low Positive** \* (Ref Interval: Negative)

Low positive reactivity to nuclear matrix protein (NXP2) detected. Strong clinical correlation is recommended.

**Myositis Interpretive Information**

See Note

INTERPRETIVE INFORMATION: Dermatomyositis and Polymyositis Panel 2

If present, myositis-specific antibodies (MSAs) are specific for myositis, and may be useful in establishing diagnosis as well as prognosis. MSAs are generally regarded as mutually exclusive with rare exceptions; the occurrence of two or more MSAs should be carefully evaluated in the context of patient's clinical presentation. Myositis-associated antibodies (MAAs) may be found in patients with CTD, including overlap syndromes, and are generally not specific for myositis. The following table will help in identifying the association of any antibodies found as either MSAs or MAAs.

Antibody Specificity . . . . .	MSAs . . . . .	MAAs
Jo-1 (histidyl-tRNA synthetase) Ab, IgG . . . . .	X	
PL-12 (alanyl-tRNA synthetase) Antibody . . . . .	X	
PL-7 (threonyl-tRNA synthetase) Antibody . . . . .	X	
EJ (glycyl-tRNA synthetase) Antibody . . . . .	X	
OJ (isoleucyl-tRNA synthetase) Antibody . . . . .	X	
SRP (Signal Recognition Particle) Ab . . . . .	X	
Mi-2 (nuclear helicase protein) Antibody . . . . .	X	
P155/140 Antibody . . . . .	X	
TIF-1 gamma (155 kDA) Ab . . . . .	X	
SAE1 (SUMO activating enzyme) Ab . . . . .	X	
MDA5 (CADM-140) Ab . . . . .	X	
NXP2 (Nuclear matrix protein-2) Ab . . . . .	X	
Ha (tyrosyl-tRNA synthetase) Ab . . . . .	X	
Ks (asparaginyl-tRNA synthetase) Ab . . . . .	X	
Zo (phenylalanyl-tRNA synthetase) Ab . . . . .	X	

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Antinuclear Antibody (ANA), HEp-2, IgG **Detected** \* (Ref Interval: <1:80)

ANA Interpretive Comment See Note

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**Homogeneous Pattern**  
Clinical associations: SLE, drug-induced SLE or JIA.  
Main autoantibodies: Anti-dsDNA, anti-histones or anti-chromatin (anti-nucleosome)

**Rods and Rings pattern**  
Clinical Associations: commonly found in HCV patients who have been treated with pegylated interferon-alpha/ribavirin combination therapy.  
Main autoantibodies: IMPDH2 (no available tests)

**List of Abbreviations**  
Antisynthetase syndrome (ARS), chronic active hepatitis (CAH), inflammatory myopathies (IM) [dermatomyositis (DM), polymyositis (PM), necrotizing autoimmune myopathy (NAM)], interstitial lung disease (ILD), juvenile idiopathic arthritis (JIA), mixed connective tissue disease (MCTD), primary biliary cholangitis (PBC), rheumatoid arthritis (RA), systemic autoimmune rheumatic diseases (SARD), Sjogren syndrome (Sjs), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), undifferentiated connective tissue disease (UCTD).

**INTERPRETIVE INFORMATION: ANA Interpretive Comment**

Presence of antinuclear antibodies (ANA) is a hallmark feature of systemic autoimmune rheumatic diseases (SARD). However, ANA lacks diagnostic specificity and is associated with a variety of diseases (cancers, autoimmune, infectious, and inflammatory conditions) and may also occur in healthy individuals in varying prevalence. The lack of diagnostic specificity requires confirmation of positive ANA by more specific serologic tests. ANA (nuclear reactivity) positive patterns reported include centromere, homogeneous, nuclear dots, nucleolar, or speckled. ANA (cytoplasmic reactivity) positive patterns reported include reticular/AMA, discrete/GW body-like, polar/golgi-like, cytoplasmic speckled or rods and rings. All positive patterns are reported to endpoint titers (1:2560). Reported patterns may help guide differential diagnosis, although they may not be specific for individual antibodies or diseases. Mitotic staining patterns not reported. Negative results do not necessarily rule out SARD.

Ha (tyrosyl-tRNA synthetase) Ab

**Positive \*** (Ref Interval: Negative)

Ha positive by line immunoassay. Band corresponding to 65 kDa observed by immunoprecipitation. Profile consistent with Ha antibody positivity.

Ks (asparaginyl-tRNA synthetase) Ab

**See Note \*** (Ref Interval: Negative)

Ks positive by line immunoassay. No bands corresponding to 65 kDa observed by immunoprecipitation. Strong clinical correlation is recommended.

Zo (phenylalanyl-tRNA synthetase) Ab

**Positive \*** (Ref Interval: Negative)

Zo positive by line immunoassay. Bands corresponding to 68 and 58 kDa observed by immunoprecipitation. Profile consistent with Zo antibody positivity.

**H=High, L=Low, \*=Abnormal, C=Critical**

**Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA, Single Pattern (Reflex for 3000082 ANA IFA AB Only Not Orderable by Clients)**

ARUP test code 3000083

ANA Pattern	Homogeneous	*
-------------	-------------	---

ANA Titer	1:640	*
-----------	-------	---

**Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA, Cytoplasmic Pattern (Reflex for 3000082 ANA IFA AB Only Not Orderable by Clients)**

ARUP test code 3000478

Cytoplasmic Titer	1:640	*
-------------------	-------	---

Cytoplasm Pattern	Rods and Rings	*
-------------------	----------------	---

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 25-022-111367  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 4 of 5 | Printed: 1/22/2025 2:43:11 PM  
4848

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PL-12 (alanyl-tRNA synthetase) Antibody	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PL-7 (threonyl-tRNA synthetase) Antibody	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
EJ (glycyl-tRNA synthetase) Antibody	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
OJ (isoleucyl-tRNA synthetase) Antibody	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SRP (Signal Recognition Particle) Ab	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Mi-2 (nuclear helicase protein) Antibody	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
P155/140 Antibody	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
TIF-1 gamma (155 kDa) Ab	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
SAE1 (SUMO activating enzyme) Ab	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
MDA5 (CADM-140) Ab	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
NXP2 (Nuclear matrix protein-2) Ab	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Myositis Interpretive Information	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Antinuclear Antibody (ANA), HEp-2, IgG	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
ANA Pattern	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
ANA Titer	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cytoplasmic Titer	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
ANA Interpretive Comment	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cytoplasm Pattern	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Ha (tyrosyl-tRNA synthetase) Ab	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Ks (asparaginyl-tRNA synthetase) Ab	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Zo (phenylalanyl-tRNA synthetase) Ab	25-022-111367	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 25-022-111367  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 5 of 5 | Printed: 1/22/2025 2:43:11 PM  
4848